NEOG vs. CLDX, NTLA, MYGN, VIVO, XRAY, MMSI, HAE, QDEL, ICUI, and STAA
Should you be buying Neogen stock or one of its competitors? The main competitors of Neogen include Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Meridian Bioscience (VIVO), DENTSPLY SIRONA (XRAY), Merit Medical Systems (MMSI), Haemonetics (HAE), QuidelOrtho (QDEL), ICU Medical (ICUI), and STAAR Surgical (STAA). These companies are all part of the "medical" sector.
Celldex Therapeutics (NASDAQ:CLDX) and Neogen (NASDAQ:NEOG) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, community ranking, media sentiment, dividends, profitability and analyst recommendations.
Neogen has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.
Celldex Therapeutics received 270 more outperform votes than Neogen when rated by MarketBeat users. Likewise, 74.91% of users gave Celldex Therapeutics an outperform vote while only 57.19% of users gave Neogen an outperform vote.
In the previous week, Neogen had 3 more articles in the media than Celldex Therapeutics. MarketBeat recorded 8 mentions for Neogen and 5 mentions for Celldex Therapeutics. Neogen's average media sentiment score of 1.29 beat Celldex Therapeutics' score of 0.91 indicating that Celldex Therapeutics is being referred to more favorably in the media.
96.7% of Neogen shares are owned by institutional investors. 3.8% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 0.7% of Neogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Neogen has a net margin of 0.17% compared to Neogen's net margin of -2,385.57%. Celldex Therapeutics' return on equity of 3.35% beat Neogen's return on equity.
Celldex Therapeutics currently has a consensus price target of $66.00, suggesting a potential upside of 98.20%. Neogen has a consensus price target of $22.50, suggesting a potential upside of 71.10%. Given Neogen's stronger consensus rating and higher possible upside, equities analysts clearly believe Celldex Therapeutics is more favorable than Neogen.
Celldex Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, Neogen has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.
Summary
Celldex Therapeutics and Neogen tied by winning 9 of the 18 factors compared between the two stocks.
Get Neogen News Delivered to You Automatically
Sign up to receive the latest news and ratings for NEOG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NEOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
